Cilag [SEP] parent company
Cilag
Cilag AG is a Swiss pharmaceutical company. Cilag is a subsidiary of American pharmaceutical giant Johnson & Johnson. The company's global marketing activities are operated by Janssen-Cilag, a merger with another Johnson & Johnson subsidiary, Janssen Pharmaceutica.
Company history.
In 1933, Swiss chemist Bernhard Joos set up a small research laboratory in Schaffhausen, Switzerland. This set the basis for the founding of "Chemische Industrie-Labor AG" (Chemical Industry Laboratory AG or Cilag) on 12 May 1936.
The
.
Cilag continues to have operations under the Cilag name in Switzerland, ranging from research and development through manufacturing and international services.
In August 2014 Cilag acquired Covagen a biopharmaceutical company which specialises in the development of multi-specific protein based therapeutics. As part of the acquisition Cilag wll gain access to Covagen’s lead drug candidate, COVA 322, a bi-specific anti-tumor necrosis factor (TNF)-alpha/anti-interleukin (IL)-17A FynomAb, is in a Phase Ib study for psoriasis.
Product history.